Cognitive Function in a Randomized Trial of Evolocumab

P. Giugliano, Robert; Mach, François; H. Zavitz, Kenton; E. Kurtz, Christopher; Im, Kyungah; Kanevsky, Estella; Schneider, Jingjing; Wang, Huei; Keech, Anthony; R. Pedersen, Terje; S. Sabatine, Marc; S. Sever, Peter; G. Robinson, Jennifer; Honarpour, Narimon; M. Wasserman, Scott; R. Ott, Brian

doi:10.1056/nejmoa1701131

Public

Cognitive Function in a Randomized Trial of Evolocumab

Published in New England Journal of Medicine • Aug 16, 2017

Authors:

Robert P. Giugliano

François Mach

Kenton H. Zavitz

Abstract

Background Findings from clinical trials of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol that result from their use are associated with cognitive deficits. Methods In a subgroup of...

Subject

Medicine

Evolocumab

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!